enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

3. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   Following years of public outcry about the high cost of inhalers, the two drugmakers — along with a third, GlaxoSmithKline — have committed to capping the out-of-pocket cost at $35 a month.

4. Fluticasone/salmeterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone/salmeterol

   In 2012, Advair was part of a larger civil settlement agreement between GlaxoSmithKline (GSK) and the United States, in which GSK agreed to pay $1.043 billion; the United States said that GSK promoted off-label uses of Advair and paid kickbacks to healthcare professionals to sell this drug, among others. [19]

5. Prescription drug prices in the United States - Wikipedia

   en.wikipedia.org/wiki/Prescription_drug_prices...

   Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.

6. Fluticasone propionate - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_propionate

   Fluticasone propionate, sold under the brand names Flovent and Flonase among others, is a glucocorticoid steroid medication. [8] When inhaled it is used for the long term management of asthma and COPD. [8]

7. USDA freezes farmer funding for some programs, conservation ...

   www.aol.com/news/usda-freezes-farmer-funding...

   CHICAGO/WASHINGTON DC (Reuters) -The U.S. Department of Agriculture has frozen some funding for farmers as it goes through a sweeping review, despite assurances from the Trump administration that ...